Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

NCT05712265 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Antipsychotic Induced Weight Gain
Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG: Miricorilant
DRUG: Fluvoxamine

Sponsor

Corcept Therapeutics